CA3142777C - Polytherapie comprenant le blocage de la semaphorine-4 d (sema4d) et therapie par dc1 - Google Patents

Polytherapie comprenant le blocage de la semaphorine-4 d (sema4d) et therapie par dc1

Info

Publication number
CA3142777C
CA3142777C CA3142777A CA3142777A CA3142777C CA 3142777 C CA3142777 C CA 3142777C CA 3142777 A CA3142777 A CA 3142777A CA 3142777 A CA3142777 A CA 3142777A CA 3142777 C CA3142777 C CA 3142777C
Authority
CA
Canada
Prior art keywords
cancer
her2
sema4d
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3142777A
Other languages
English (en)
Other versions
CA3142777A1 (fr
Inventor
Brian Czerniecki
Krithika Kodumudi
Elizabeth Evans
Original Assignee
H Lee Moffitt Cancer Center And Research Institute Inc A Florida Non Profit Corp
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center And Research Institute Inc A Florida Non Profit Corp, Vaccinex Inc filed Critical H Lee Moffitt Cancer Center And Research Institute Inc A Florida Non Profit Corp
Priority claimed from PCT/US2020/038719 external-priority patent/WO2020257640A1/fr
Publication of CA3142777A1 publication Critical patent/CA3142777A1/fr
Application granted granted Critical
Publication of CA3142777C publication Critical patent/CA3142777C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des compositions et des méthodes comprenant l'administration de cellules dendritiques pulsées et d'un inhibiteur de molécules immunorégulatrices pour le traitement du cancer.
CA3142777A 2019-06-21 2020-06-19 Polytherapie comprenant le blocage de la semaphorine-4 d (sema4d) et therapie par dc1 Active CA3142777C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865027P 2019-06-21 2019-06-21
US62/865,027 2019-06-21
PCT/US2020/038719 WO2020257640A1 (fr) 2019-06-21 2020-06-19 Polythérapie comprenant le blocage de la sémaphorine-4 d (sema4d) et thérapie par dc1

Publications (2)

Publication Number Publication Date
CA3142777A1 CA3142777A1 (fr) 2020-12-24
CA3142777C true CA3142777C (fr) 2025-10-07

Family

ID=

Similar Documents

Publication Publication Date Title
US12201719B2 (en) Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
US20230042913A1 (en) A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof
ES2894335T5 (es) Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
JP7473474B2 (ja) 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
US20210070869A1 (en) Axl-specific antibodies for cancer treatment
JP2017537892A (ja) 疾患の処置のための併用療法
US20230235073A1 (en) Anti-cd36 antibodies and their use to treat cancer
JP2021534165A (ja) 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用
WO2023044432A2 (fr) Ciblage de kras mutant avec un iga spécifique de mutation
EP2766045B1 (fr) Traitement personnalisé du cancer du sein par un diagnostic
US20210393793A1 (en) Axl-specific antibodies for treatment of non-small cell lung cancer
CA3142777C (fr) Polytherapie comprenant le blocage de la semaphorine-4 d (sema4d) et therapie par dc1
US20230086099A1 (en) Combination therapy for treatment of cancer and cancer metastasis
RU2801828C2 (ru) Комбинированная терапия блокированием семафорина 4d (sema4d) и терапией дк1
US20250376522A1 (en) Targeting Cells with a Combination of CXCR2 Inhibition and CD47 Blockade
WO2024036232A2 (fr) Anticorps bispécifiques et leurs utilisations
US20240034788A1 (en) Abscopal therapy for cancer
US20250230260A1 (en) Cdrs for glycosylated acat1
WO2024159105A1 (fr) Méthodes de traitement du cancer comprenant l'administration de dc intratumorales en combinaison avec un anticorps monoclonal igg systémique
US20260008844A1 (en) Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer
WO2024158763A2 (fr) Molécules de liaison lilrb2 et méthodes d'utilisation
CN117355333A (zh) 包含抗tm4sf1抗体和免疫治疗药剂的组合及其使用方法
CA2997130C (fr) Anticorps specifiques contre le domaine d'immunoglobuline de lymphocyte t et itim (tigit)
JP2025530130A (ja) 抗ｔｍｅｆｆ２×ｃｄ３二重特異性抗体でがんを治療する方法